Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Asthma drug from the garden center

14.09.2017

The coralberry could offer new hope for asthmatics: researchers at the University of Bonn have extracted a new kind of active pharmaceutical ingredient from its leaves to combat this widespread respiratory disease. In mice, it almost completely inhibits the characteristic contraction of the airways. The plant itself is not exotic: it can be found in any well-stocked garden center. The study is published in the renowned journal Science Translational Medicine.

The coralberry is no outstanding beauty most of the year. This however changes in the winter months: it then forms striking, bright red berries, which make it a popular ornamental plant during this time.


The leaves of the coralberry (Ardisia crenata) contain the natural substance FR900359.

© Photo: Raphael Reher/Daniela Wenzel/Uni Bonn


Prof. Dr. Daniela Wenzel, Alexander Seidinger, Annika Simon and Dr. Michaela Matthey (from left).

(c) Photo: Katharina Wislsperger/Ukom-UKB

Nevertheless, the scientists involved in the study are interested in the plant for another reason: the leaves of the coralberry contain a substance with the cryptic name FR900359. It is assumed that this could be suitable as a medication against certain diseases, despite the fact that Ardisia crenata (its botanical name) has so far been largely disregarded by science.

Researchers at the Institutes of Physiology I, Pharmaceutical Biology and Pharmaceutical Chemistry at the University of Bonn, together with asthma specialists from Nottingham (United Kingdom), have now published a study that could change this.

They found that FR900359 is very effective at preventing the bronchial muscles from contracting. Asthmatics regularly suffer from these pronounced contractions preventing adequate ventilation of the lungs. The resulting shortness of breath can be life-threatening.

More effective than common medicines

The new compound relieves these spasms – and is supposedly more effective and has a more prolonged action than the most common asthma drug salbutamol. “However, we have so far only tested the substance in asthmatic mice,” explains junior professor Dr. Daniela Wenzel. Wenzel is doing research in respiratory diseases at the Institute of Physiology I at the University of Bonn; she was the leader of the study.

The idea to test FR900359 came from the Institute of Pharmaceutical Biology: there, the scientists managed to isolate and characterize the active pharmaceutical substance from the leaves of the coralberry. “This compound inhibits critical signaling molecules in our cells, the Gq proteins,” explains Wenzel. Gq proteins exert key functions in many processes in the body – including control of the airway tone.

Normally, interaction of various signaling pathways induces narrowing of the airways. Inhibition of individual signaling pathways can reduce the contraction of the respiratory tract. However, this does not make it possible to completely prevent such contractions in patients with severe asthma. The various contracting signals converge on Gq proteins and trigger airway spasm. “When we inhibit the activation of Gq proteins with FR900359, we achieve a much greater effect,” emphasizes Dr. Michaela Matthey from the Institute of Physiology I.

This worked exceptionally well in asthmatic mice in the study. “We were able to prevent the animals from reacting to allergens such as house dust mite with a narrowing of the bronchia,” Wenzel is pleased to report. There were hardly any side effects, as the active pharmaceutical ingredient could be applied via inhalation to the respiratory tract and thus only reached the systemic circulation in small quantities.

However, it is not known whether the substance is also suitable for use in people. Although the scientists have already been able to show that human bronchial muscle cells in a petri dish and isolated human airways react in a similarly promising manner, further tests, which could take years, are required prior to its application in people.

Nevertheless, the work is already a great success. This is no coincidence: the German Research Foundation (DFG) funds the research group “G protein signal cascades: creating new pharmaceutical concepts with molecular probes and active pharmaceutical ingredients” at the University of Bonn.

The aim is to pharmaceutically influence central signaling molecules such as the Gq proteins to identify novel substances for the treatment of certain diseases. Physiologists and pharmacists at the University collaborate closely within the research group; the current study is the result of this successful scientific interaction.

Publication: Michaela Matthey, Richard Roberts, Alexander Seidinger, Annika Simon, Ralf Schröder, Markus Kuschak, Suvi Annala, Gabriele M König, Christa E Müller, Ian P Hall, Evi Kostenis, Bernd K Fleischmann, Daniela Wenzel: Targeted inhibition of Gq signaling induces airway relaxation in mouse models of asthma; Science Translational Medicine; DOI: 10.1126/scitranslmed.aag2288

Contact:

Junior professor Dr. Daniela Wenzel
Institute of Physiology I
Life & Brain Center
Faculty of Medicine
University of Bonn
Tel. +49 (0)228/6885-216
E-mail: dwenzel@uni-bonn.de

Prof. Bernd. K. Fleischmann
Institute of Physiology I
Life & Brain Center
Faculty of Medicine
University of Bonn
Tel. +49 (0)228/6885-200
E-mail: bernd.fleischmann@uni-bonn.de

Johannes Seiler | idw - Informationsdienst Wissenschaft
Further information:
http://www.uni-bonn.de

Further reports about: Asthma Biology Physiology airway proteins respiratory tract signaling molecules

More articles from Health and Medicine:

nachricht 'Icebreaker' protein opens genome for t cell development, Penn researchers find
21.02.2018 | University of Pennsylvania School of Medicine

nachricht Similarities found in cancer initiation in kidney, liver, stomach, pancreas
21.02.2018 | Washington University School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

Im Focus: Interference as a new method for cooling quantum devices

Theoretical physicists propose to use negative interference to control heat flow in quantum devices. Study published in Physical Review Letters

Quantum computer parts are sensitive and need to be cooled to very low temperatures. Their tiny size makes them particularly susceptible to a temperature...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Researchers invent tiny, light-powered wires to modulate brain's electrical signals

21.02.2018 | Life Sciences

The “Holy Grail” of peptide chemistry: Making peptide active agents available orally

21.02.2018 | Life Sciences

Atomic structure of ultrasound material not what anyone expected

21.02.2018 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>